[Immunotherapy of Gastrointestinal Stromal Tumors]

Area of Science:

• Oncology
• Immunology
• Gastroenterology

Background:

• Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract.
• GISTs exhibit poor response to conventional radiochemotherapy, with complete surgical excision being the primary curative option.
• KIT or PDGFRA gene mutations drive GIST development but can lead to drug resistance and relapse under targeted therapy.

Purpose of the Study:

• To explore the role of the immune microenvironment in GISTs.
• To evaluate the potential of immunotherapy for GIST treatment.
• To understand how immune cells influence GIST development and targeted therapy efficacy.

Main Methods:

• Analysis of tumor-infiltrating immune cells in GIST samples.
• Review of preclinical and clinical studies on GIST immunotherapy.
• Investigation of immune cell involvement in GIST pathogenesis and response to therapy.

Main Results:

• GISTs possess diverse tumor-infiltrating immune cells and complex immune microenvironments.
• Immune cells significantly influence GIST occurrence, development, and response to targeted therapies.
• Preclinical and clinical data support the feasibility and effectiveness of immunotherapy for GISTs.

Conclusions:

• Immunotherapy represents a promising therapeutic strategy for GISTs, particularly in cases of drug resistance.
• Understanding the GIST immune microenvironment is crucial for optimizing treatment outcomes.
• Further research into GIST immunotherapy could lead to improved patient survival rates.